什么可以预测质母细胞瘤的生存率? 一个基于人群的临床管理和结果变化的研究
B Fekete1,2, K Werlenius2,3, M Tisell1,4
1Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Frontiers in surgery
|September 15, 2023
概括
随着目前的治疗方法,质母细胞瘤的存活率有所改善,与早期的队列相比显著增加. MGMT促进剂高甲基化是预测质母细胞瘤患者更长生存的关键因素.
科学领域:
- 神经瘤学神经瘤学
- 手术瘤学手术瘤学
- 临床流行病学临床流行病学
背景情况:
- 质母细胞瘤是一种具有攻击性的原发性脑瘤,预后不佳.
- 目前的多式疗法提供了有限的生存益处.
- 确定预后因素对于改善患者的治疗结果至关重要.
研究的目的:
- 确定质母细胞瘤患者生存的预后因素.
- 随着时间的推移,比较结果和管理战略.
- 评估分子瘤诊断对质母细胞瘤治疗的影响.
主要方法:
- 在2012-2016年间对222名成年质母细胞瘤患者进行手术的回顾性分析.
- 扩展Poisson回归模型用于识别预后变量.
- 与2004-2008年的历史队列进行比较.
主要成果:
- 平均整体存活时间从早期队列的0.73年大幅增加到1.07年.
- 超甲基化MGMT促销剂,非中心瘤位置和完全切除与更长的生存时间有关.
- 年龄较小,并发症较少,表现较好的状态也预测了改善的结果.
结论:
- 目前的标准质母细胞瘤治疗适度改善了中位生存率.
- MGMT促进剂高甲基化是质母细胞瘤生存的最强的预测因子.
- 预后因素包括瘤特征,患者状态和治疗完整性.
相关概念视频
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Comparing the Survival Analysis of Two or More Groups
220
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
220


